A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

Chung, A. W., Anand, K., Anselme, A. C., Chan, A. A., Gupta, N., Venta, L. A., Schwartz, M. R., Qian, W., Xu, Y., Zhang, L., Kuhn, J., Patel, T., Rodriguez, A. A., Belcheva, A., Darcourt, J., Ensor, J., Bernicker, E., Pan, P., Chen, S., Lee, D. J., Niravath, P. A., & Chang, J. C. Dec 15 2021. In: Science Translational Medicine, Vol 13, Issue 624.

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Li, Z., Liu, H., He, J., Wang, Z., Yin, Z., You, G., Wang, Z., Davis, R. E., Lin, P., Bergsagel, P. L., Manasanch, E. E., Wong, S. T. C., Esnaola, N. F., Chang, J. C., Orlowski, R. Z., Yi, Q. & Yang, J., Jan 5 2021, In: Cell Metabolism. 33, 1, p. 78-93.e7

Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic

Darcourt, J. G., Aparicio, K., Dorsey, P. M., Ensor, J. E., Zsigmond, E. M., Wong, S. T., Ezeana, C. F., Puppala, M., Heyne, K. E., Geyer, C. E., Phillips, R. A., Schwartz, R. L. & Chang, J. C., Jan 1 2021, In: JCO oncology practice. 17, 1, p. e36-e43

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer

Koca, E., Niravath, P. A., Ensor, J., Patel, T., Li, X., Hemati, P., Wong, H., Qian, W., Boone, T., Zhao, J., Ramshesh, P. V., Cohen, A. L., Murthy, A., Nair, S., Darcourt, J., Belcheva, A., Kaklamani, V. G. & Chang, J. C., 2021, (Accepted/In press) In: Breast Cancer Research and Treatment.
View All Publications